UPPSALA, Sweden, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the achievement of more than one thousand peer-reviewed publications citing the use of Olink® Proximity Extension Assay (PEA) technology, underscoring the widespread adoption and successful application of its protein biomarker solutions by the scientific community.
The 100th paper citing Olink technology was published in 2017, with the rate of publication accelerating rapidly since then to encompass pioneering efforts across all major regions worldwide, in-step with the rapid growth of Olink’s global business. Over 230 new articles have already been published so far in 2022, pushing the total to more than 1,000. Overall, PEA has helped enable publication in some of the most prestigious journals in the world, such as The Lancet, Nature, Nature Medicine, Science and Cell, and others.
“We are delighted that so many outstanding scientists have been able to use our protein biomarker solutions to further their important research and produce this exceptional body of high-quality publications,” said Dr. Ida Grundberg, Chief Scientific Officer, Olink. “Peer-reviewed publications are the lifeblood of the research community, representing a key measure of success for scientists, driving progress towards a deeper biological understanding of human health and disease, and providing the foundation to develop new and better therapies.”
Olink’s protein biomarker solutions are applicable to almost any type of research into human biology, which is reflected in an extraordinarily broad range of application areas covered by the published literature. Scientists have applied Olink to everything from in vitro experiments in basic biological research, through a wide variety of clinical studies using patient samples, as well as in drug development-related applications in association with clinical trials. All major disease areas have been investigated using Olink panels, with particularly robust application to cardiovascular, metabolic, neurological, and inflammatory/immunological diseases, oncology/immunotherapy, and in the past few years, COVID-19 research.
The unique scalability of Olink’s technology, from high-plex to low-plex proteomics, is also on display in this collective effort, from smaller studies with tens of samples looking at fewer than 100 proteins (with Olink® Target 48/96 panels) to major international projects such as the UK Biobank Pharma Proteomics Project measuring almost three thousand proteins in tens of thousands of samples (with Olink® Explore 3072).
Over time and as the Olink offering has expanded, there has been a clear trend towards broader studies measuring large numbers of proteins to answer increasingly complex questions. There is also a clear, growing trend for more “systems biology” studies in which proteomics is combined with other omics technologies such as genomics, transcriptomics, and metabolomics. Olink believes this multi-omics approach is needed to help drive a deep understanding of human health and disease, and to promote healthcare’s progress around precision medicine.
The two principal scientists involved in the very first Olink study to be published give their perspectives on the 1000 publication milestone:
“It has been quite the journey”, said Stefan Enroth, Associate Professor in Computational Genomics at Uppsala University, Sweden. “Starting from the very first Target 96 Oncology I panel that we used in our first Olink study, branching out to both the focused, custom small biomarker panels with readout in absolute concentrations and the large exploratory Explore panels measuring thousands of proteins at once. Being early adopters of the PEA-technology has propelled our studies of protein biomarkers in relation to health and disease in ways we could not have imagined.”
“The Olink multiplex PEA platform is a transformative -omics technology, enabling high throughput, highly multiplexed and precise protein analysis”, said Ulf Gyllensten, Professor of Medical Molecular Genetics at Uppsala University, Sweden. “As early adopters of PEA we have successfully used this to identify biomarkers for gynecological cancer. NGS has completely changed the genomics field. The Explore technology promises to be as transformative for the proteomics analysis. Coupling PEA with a NGS readout provides unprecedented opportunities for exhaustive analysis of the human proteome”.
Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com
Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com
About
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
Forward-Looking Statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Attachment
